Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.

Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Müller M, Sefrin JP, Schröder M, Sykora J, Fricke H, Hill O, Gieffers C, Thiemann M.

J Immunother Cancer. 2019 Jul 19;7(1):191. doi: 10.1186/s40425-019-0671-4.

2.

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.

Thiemann M, Richards DM, Heinonen K, Kluge M, Marschall V, Merz C, Redondo Müller M, Schnyder T, Sefrin JP, Sykora J, Fricke H, Gieffers C, Hill O.

Front Oncol. 2018 Sep 19;8:387. doi: 10.3389/fonc.2018.00387. eCollection 2018.

3.

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.

Merz C, Sykora J, Marschall V, Richards DM, Heinonen K, Redondo Müller M, Thiemann M, Schnyder T, Fricke H, Hill O, Gieffers C.

J Immunother. 2018 Nov/Dec;41(9):385-398. doi: 10.1097/CJI.0000000000000246.

PMID:
30273198
4.

Reactive oxygen species contribute toward Smac mimetic/temozolomide-induced cell death in glioblastoma cells.

Seyfrid M, Marschall V, Fulda S.

Anticancer Drugs. 2016 Nov;27(10):953-959.

PMID:
27669171
5.

Smac mimetic-induced upregulation of interferon-β sensitizes glioblastoma to temozolomide-induced cell death.

Marschall V, Fulda S.

Cell Death Dis. 2015 Sep 17;6:e1888. doi: 10.1038/cddis.2015.235.

6.

Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.

Lindemann C, Marschall V, Weigert A, Klingebiel T, Fulda S.

Neoplasia. 2015 Jun;17(6):481-9. doi: 10.1016/j.neo.2015.05.002.

7.

Porosity and mechanically optimized PLGA based in situ hardening systems.

Schloegl W, Marschall V, Witting MY, Volkmer E, Drosse I, Leicht U, Schieker M, Wiggenhorn M, Schaubhut F, Zahler S, Friess W.

Eur J Pharm Biopharm. 2012 Nov;82(3):554-62. doi: 10.1016/j.ejpb.2012.08.006. Epub 2012 Aug 28.

PMID:
22947486
8.

Splice variants of the P2X7 receptor reveal differential agonist dependence and functional coupling with pannexin-1.

Xu XJ, Boumechache M, Robinson LE, Marschall V, Gorecki DC, Masin M, Murrell-Lagnado RD.

J Cell Sci. 2012 Aug 15;125(Pt 16):3776-89. doi: 10.1242/jcs.099374. Epub 2012 May 2.

9.

Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.

Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, Vucic D, Debatin KM, Fulda S.

Oncogene. 2013 Feb 21;32(8):988-97. doi: 10.1038/onc.2012.108. Epub 2012 Apr 2.

PMID:
22469979
10.

NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis.

Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, Vellanki SH, Hehlgans S, Rödel F, Debatin KM, Ludolph AC, Fulda S.

Mol Cancer Ther. 2011 Oct;10(10):1867-75. doi: 10.1158/1535-7163.MCT-11-0218. Epub 2011 Aug 22.

11.

Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts.

Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC, Murrell-Lagnado R.

Br J Pharmacol. 2012 Feb;165(4):978-93. doi: 10.1111/j.1476-5381.2011.01624.x.

Supplemental Content

Loading ...
Support Center